))
Adrian Rawcliffe, Adaptimmune
Manage episode 469746179 series 3347911
Content provided by Life Sciences Pennsylvania. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Life Sciences Pennsylvania or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.
This episode features Adrian (Ad) Rawcliffe, CEO, Adaptimmune, recipient of the Life Sciences PA 2024 Patient Impact Award.
Ad shares the story behind TECELRA - the first FDA approved engineered cell therapy for a solid tumor. Learn about the journey leading up to this groundbreaking approval, the challenges of bringing a cell therapy to market and the next steps for Adaptimmune in the landscape of tumor treatments.
61 episodes
Share
